Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
about
Combination anastrozole and fulvestrant in metastatic breast cancerNatural products as aromatase inhibitorsBazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterusDesign and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activitiesOvercoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.Aromatase inhibitors and xenograft studies.Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitorsERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancerA kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancerThe discovery and mechanism of action of letrozole.The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancerExtended adjuvant therapy with letrozole: reducing the risk of recurrence.Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.Integration of endocrine therapy with targeted agents.Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma.Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.Role of fulvestrant in the management of postmenopausal breast cancer.An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.Effect of selumetinib on the growth of anastrozole-resistant tumors.Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem.Anastrozole: a new gold standard of hormonal treatment for breast cancer?A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer.Growth of human breast cancers in Peromyscus.Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.The Cytochrome P450 Enzyme Responsible for the Production of (Z)-Norendoxifen in vitro.Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidenceEndocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and LiteratureEndocrine Resistance in Breast Cancer
P2860
Q24595386-F1E6E16A-93E3-499C-8C1E-D2B3E83C84CBQ24620153-0B1B6D58-3188-4053-BF9F-DBD3D48E47FAQ30413295-B604DD3F-76E4-41BE-AECF-7A4C80BEB387Q30438632-B1645DF0-6EC9-4E6D-B07A-E5F827B3523EQ33700933-A3508FA8-BF35-4E38-9D74-3D1049D55316Q33941574-A2DF5879-EE85-4FDB-B1A3-E1C551CA64DAQ33949822-A5048F50-733B-4FBE-9A9E-D4FF56697887Q33956843-68283D30-BB89-4508-8981-CD2606CCF44CQ34466243-1F9EE7BD-5C15-4B96-BCEB-68AB76237D80Q34657786-BFA6B2C1-9E7F-446A-A03A-72E60A28EEAEQ35043020-381BCAEC-3B3E-426F-B65D-DE7C2573BEF7Q35091502-7B1D6872-2F06-4FB0-A1E1-FC5E735AD27CQ35479617-BD7294E5-1B9A-477D-AC83-D54010804B27Q35501973-41FA4102-1D8C-40A4-8ED7-7221C4566657Q36026408-1BF29A59-C395-4401-B28F-3F99B63262E9Q36432163-80EDEF1D-AB3D-4267-8E60-43F7A2C85AAAQ36500530-904C2902-3A95-400B-AFA0-8186BAD92CFDQ36646986-CE864E09-1FC3-4881-ADE0-65C3C1C5ED6EQ36684234-A5656C3C-9351-4605-9B00-866A63B1E5DBQ36782224-58969500-4E3E-4BE4-A40A-A3740AE01053Q36919229-E6B6710D-9780-41FE-993A-90820C544BE5Q37039801-CC4ACA7B-C4F7-40CD-AFF0-2B7D4D80BAC4Q37125984-947286FD-BCCD-4111-8B1C-86874739E63BQ37449530-B49776E4-1C08-4E5C-B3E8-1E47B58FAA48Q37697034-15D660D6-0947-469F-AC60-790198EF2D39Q37952234-2A34A795-C98A-4437-8E23-B407EC5C6743Q37954137-C57478CD-8A4B-43CD-8E88-DAA6FD982DF8Q39178760-1028E2E4-132C-4299-AD01-0A52FCC0BD0EQ39779772-8A0ECAD0-F290-4B9E-B625-A57C15B2EC63Q42755954-6143A63D-7747-4984-BD0C-71FC1AF5FDC1Q43267073-0D744F5B-51FA-43B9-A15B-B6EA80746242Q43645692-99D1CE2B-ACA0-45BF-9A5E-D2B30A70DE16Q48223872-CD6F5180-5D03-4F76-9BC2-826D7674F2BCQ48226422-89AC8250-11C5-4F96-80A6-D0780CC566A2Q52758170-DD978E88-9858-4897-A3F4-3978BEE49643Q54349937-CCC4259B-F8E6-4D79-B098-23E52187E1CBQ57107345-356BE8C4-CEB1-4138-AF42-2CB4B7415AE3Q57108908-46F245D8-7317-4749-8D5A-C99FF561FBB5Q59072640-D64C4E9A-EBC6-4B84-AB1A-2B7320E593E8
P2860
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Additive antitumor effect of a ...... enopausal breast cancer model.
@en
type
label
Additive antitumor effect of a ...... enopausal breast cancer model.
@en
prefLabel
Additive antitumor effect of a ...... enopausal breast cancer model.
@en
P2093
P1433
P1476
Additive antitumor effect of a ...... enopausal breast cancer model.
@en
P2093
Angela M H Brodie
Danijela Jelovac
Luciana Macedo
Olga G Goloubeva
Venkatesh Handratta
P304
P356
10.1158/0008-5472.CAN-04-2782
P407
P577
2005-06-01T00:00:00Z